Advances in the research of pharmacogenomics of cyclophosphamide / 药学学报
Acta Pharmaceutica Sinica
; (12): 971-976, 2014.
Article
in Zh
| WPRIM
| ID: wpr-299181
Responsible library:
WPRO
ABSTRACT
Cyclophosphamide (CPA) is the most common alkylating antineoplastic agent, as well as a strong immunosuppressant that is frequently applied to autoimmune diseases and organ transplantation. It is metabolized by cytochrome P450 oxidases (CYPs) to its active metabolite which played a critical role in therapy. CPA has serious and even fatal side effects, and its efficacy and adverse reactions are significantly varied among individuals. In this review, the association of the genetic polymorphisms in the metabolic enzymes and transporters involved in the disposition of CPA with the efficacy and adverse effects of CPA were summarized, thereby providing fundamental reference for further pharmacogenomic study of CPA.
Full text:
1
Index:
WPRIM
Main subject:
Pharmacogenetics
/
Pharmacology
/
NADPH-Ferrihemoprotein Reductase
/
Antineoplastic Agents, Alkylating
/
Cyclophosphamide
/
Metabolism
Limits:
Humans
Language:
Zh
Journal:
Acta Pharmaceutica Sinica
Year:
2014
Type:
Article